Multiple myeloma preparative regimens for high-dose therapy and autologous transplantation: what's new?

被引：0
|
作者：
Aljitawi, Omar S. [1 ]
McGuirk, Joseph P. [1 ]
机构：
[1] Univ Kansas, Med Ctr, Blood & Marrow Transplant Program, Kansas City, KS 66103 USA
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2012年 / 1卷 / 01期
关键词：
autologous; chemotherapy; multiple myeloma; preparative regimen; review; transplant; STEM-CELL TRANSPLANTATION; CONDITIONING REGIMEN; PHASE-II; RANDOMIZED-TRIAL; ALLOGENEIC TRANSPLANTATION; INTERGROUPE FRANCOPHONE; STANDARD CHEMOTHERAPY; 200 MG/M(2); MELPHALAN; CYCLOPHOSPHAMIDE;
D O I：
10.2217/CER.11.11
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
High-dose chemotherapy and autologous stem cell transplantation remains a standard procedure in relatively young and selected older patients with multiple myeloma. High-dose melphalan has remained the chemotherapeutic agent of choice based on earlier prospective randomized trials. Despite investigations involving different combinations of chemotherapeutics, radiation and novel agents with and without melphalan, none of these alternative preparative regimens have demonstrated superiority to high-dose melphalan used as a single agent in multiple published studies. In this article, we review the published literature regarding preparative regimens used in patients with multiple myeloma undergoing autologous stem cell transplantation.
引用
收藏
页码：57 / 70
页数：14
相关论文
共 50 条
  • [1] High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma
    Ali, Mohammad O.
    Al Hadidi, Samer
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (09): : 572 - 580
  • [2] Historical Perspective of High-Dose Therapy Followed by Autologous Stem Cell Transplantation in Multiple Myeloma
    Cohen, Inbar
    Vaxman, Iuliana
    Gertz, Morie A.
    ACTA HAEMATOLOGICA, 2024,
  • [3] High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma
    Solomon, Scott R.
    Brown, Stacey
    Shegda, Nancy
    Jackson, Katelin C.
    Zhang, Xu
    Bashey, Asad
    Holland, H. Kent
    Morris, Lawrence E.
    Solh, Melhem
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (08): : 486.e1 - 486.e7
  • [4] High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma
    Benson, Don M., Jr.
    Elder, Patrick J.
    Lin, Thomas S.
    Blum, William
    Penza, Sam
    Avalos, Belinda
    Copelan, Edward
    Farag, Sherif S.
    LEUKEMIA RESEARCH, 2007, 31 (08) : 1069 - 1075
  • [5] Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
    Rodriguez, Tulio E.
    Hari, Parameswaran
    Stiff, Patrick J.
    Smith, Scott E.
    Sterrenberg, Danielle
    Vesole, David H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (08) : 1391 - 1396
  • [6] Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma
    Miyamoto, Toshihiro
    Yoshimoto, Goichi
    Kamimura, Tomohiko
    Muta, Tsuyoshi
    Takashima, Shuichiro
    Ito, Yoshikiyo
    Shiratsuchi, Motoaki
    Choi, Ilseung
    Kato, Koji
    Takenaka, Katsuto
    Iwasaki, Hiromi
    Takamatsu, Yasushi
    Teshima, Takanori
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 98 (03) : 337 - 345
  • [7] Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib
    Aypar, Eda
    Izzettin, Fikret Vehbi
    Aki, Sahika Zeynep
    Sancar, Mesut
    Yegin, Zeynep Arzu
    Turkoz-Sucak, Gulsan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (04) : 281 - 289
  • [8] Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma
    Chen, A. I.
    Negrin, R. S.
    McMillan, A.
    Shizuru, J. A.
    Johnston, L. J.
    Lowsky, R.
    Miklos, D. B.
    Arai, S.
    Weng, W-K
    Laport, G. G.
    Stockerl-Goldstein, K.
    BONE MARROW TRANSPLANTATION, 2012, 47 (04) : 516 - 521
  • [9] Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
    Byun, Ja Min
    Lee, Jayoun
    Shin, Sang-Jin
    Kang, Minjoo
    Yoon, Sung-Soo
    Koh, Youngil
    BLOOD RESEARCH, 2018, 53 (02) : 105 - 109
  • [10] Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation
    Fenk, Roland
    Liese, Vanessa
    Neubauer, Florian
    Bruns, Ingmar
    Kondakci, Mustafa
    Balleisen, Sebastian
    Saure, Christian
    Schroeder, Thomas
    Haas, Rainer
    Kobbe, Guido
    LEUKEMIA & LYMPHOMA, 2011, 52 (08) : 1455 - 1462
12345